Business Wire

CA-AIRSPACE

17.3.2021 14:02:14 CET | Business Wire | Press release

Share
Airspace Granted Patent for Its Industry-Changing Logistics Management System

Airspace today announced it has been granted a U.S. patent for its optimized logistics management system as of March 2. The patent covers the system, method, and computer programming of the logistical and graphical presentation of the most optimal path for transporting goods from a pickup location to a destination location at lowest transit cost and minimal risk.

Airspace leverages its patented technology and world-class team to provide certainty in the time-critical logistics space through unrivaled speed and shipment transparency . The routing operation is arguably the most important step in the logistical transportation process because the optimal route saves both money and time, while enabling customers to monitor progress along the route provides transparency.

“This technology is a game-changer for the supply chain and logistics industry,” said Ryan Rusnak , co-founder and CTO at Airspace.

Airspace’s technology calculates the best routes in less than a second instead of the typical 30 minutes or more that are standard in the time-critical shipping industry. The router generates a time and space expectation of where each order should be at any given time, which is checked via distributed sensors. Even if an expected flight is canceled, the technology immediately establishes a new plan and tracks it. Airspace provides automated notifications in real time to the customer instead of having to wait for personal contact calls, generating leading indicators rather than lagging ones.

“Our transparency with this process creates trust and confidence for both shippers and receivers,” said Rusnak. “We believe we are setting a new standard for the logistics industry.”

Logistical challenges are difficult because most shipments don’t start at an airport; they start at an arbitrary place such as a lab, warehouse, hospital, and so on. Airspace’s technology takes into consideration ground travel time as well, allowing for traffic to and from nearby airports to the final destination. This technology can provide the difference between life and death, for example, in the case of organs for transplant.

“If you choose a route that doesn’t give the driver enough time, you set the shipment up for failure. Create a route that is too conservative, and you risk losing the last flight that gets the package there when it’s needed,” said Nick Bulcao , co-founder and CEO of Airspace. “This is the extremely difficult optimization challenge that only Airspace can solve today, using our proprietary software and artificial intelligence. We are extremely proud of our inventors and pleased that our technology can make a real difference.”

Airspace, which recently closed its Series C funding round , is positioned to provide the best customer experience for clients while relentlessly analyzing data to address ongoing needs. It continues to grow, focused on making international expansion as seamless as possible by blending operations and R&D for the benefit of the industry.

About Airspace

Airspace, founded in 2016, has grown to be a leading global delivery network for time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through its people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints, Airspace surfaces more information than any other provider, increasing trust and transparency of the supply chain. To learn more, visit www.airspace.com . Follow Airspace: Twitter , Facebook , Instagram and LinkedIn .

Link:

ClickThru

Social Media:

https://www.facebook.com/AirspaceLogistics/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release

‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub

Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release

New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki

Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release

90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release

For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye